New FDA Board to Handle Exclusivity Decisions

Published Online: Friday, December 14, 2012
A board within the FDA’s Center for Drug and Evaluation and Research (CDER) is intended to help the agency make consistent decisions on marketing exclusivity periods, according to an announcement on FDA.gov.

Although the CDER Exclusivity Board will not handle 180-day generic drug exclusivity, it will focus on exclusivity for new chemical entities, new clinical trials, and biologic products. Its primary focus is clarity and consistency, but it will not make recommendations in all cases, the FDA stated.

In addition, it is expected to collaborate with offices within the FDA that handle generic, pediatric, or orphan disease exclusivity, though those areas are not a primary focus.

Although it was only recently announced, the board began making decisions in April 2012, and typically meets once to twice per month.

Related Articles
Although clinical trials have indicated that intraocular pressure-lowering medications are effective in patients with open-angle glaucoma, new research suggests that the medications may not be as effective in real-world settings.
Our guide to the latest mobile health apps, including Pharmacy Times OTC Guide and apps for pharmacy techs studying for certification, disease detectives, allergy forecasts, and clinical trials.
Numerous studies have quantified the widespread practice of prescribing drugs off-label, but many patients are unaware that it is allowed, according to a new analysis.
Latest Issues
$auto_registration$